LCN2 and inflammatory breast carcinoma: Finally, using nanoliposomal formulations to deliver LCN2-siRNAs, as reported by Guo et al., or using LCN2 inhibitors targeting the LCN2-calyx, as we showed in this study, represent feasible approaches to develop new IBC treatments [32].